U.S. markets closed

TILT Holdings Inc. (TLLTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5000-0.0190 (-3.66%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5190
Open0.5298
BidN/A x N/A
AskN/A x N/A
Day's Range0.4931 - 0.5350
52 Week Range0.3400 - 0.7500
Volume289,711
Avg. Volume895,869
Market Cap161.265M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-2.0790
Earnings DateJun 21, 2021 - Jun 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • OTC Markets Group Announces Quarterly Index Performance and Rebalancing
    PR Newswire

    OTC Markets Group Announces Quarterly Index Performance and Rebalancing

    OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the first quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index.

  • TILT Holdings Reports Fourth Quarter and Full-Year 2020 Financial Results Including First Full-Year of Positive Adjusted EBITDA
    GlobeNewswire

    TILT Holdings Reports Fourth Quarter and Full-Year 2020 Financial Results Including First Full-Year of Positive Adjusted EBITDA

    Full-year 2020 Adjusted EBITDA of $16.9 million compared to Adjusted EBITDA loss of $0.8 million in 2019 Full-year 2020 cash from operating activities improved $34.2 million compared to 2019 Full-year 2020 cannabis revenue increased 41% compared to 2019 Full-year cash expenses decreased 30% compared to 2019 PHOENIX, April 15, 2021 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (CSE: TILT) (OTCQB: TLLTF) a provider of business solutions to the global cannabis industry that includes inhalation technologies, cultivation, manufacturing, processing, brand development and retail, reported its financial and operating results for the three and twelve-months ended December 31, 2020. All financial information is provided in U.S. dollars except where otherwise indicated. Results of Yaris Acquisition, LLC and its subsidiaries (together, “Blackbird”) have been reclassified as discontinued operations on the income statement and statement of cash flows. All periods have been updated to reflect this change. “The primary focus in 2020 was for TILT to become profitable, putting in place the pieces necessary to achieve scale and engage in a steady and sustainable growth trajectory,” said Gary Santo, President of TILT. “We made a number of key decisions throughout the year that have already started to pay off, allowing the Company to have a strong finish to 2020, producing $16.9 million in Adjusted EBITDA and $16.7 million in cash from operating activities for the year. We look to carry that momentum into 2021 and are already off to a great start across all business units, supporting management’s previously announced full-year 2021 revenue guidance of $205 million to $210 million and Adjusted EBITDA guidance of $30 million to $32 million.” “TILT underwent significant changes in 2020,” added Mark Scatterday, CEO of TILT. “Through the tireless efforts of our team we were able to stabilize our foundation, solidify our strategy and focus on how best to deploy available resources towards our high-growth plant touching assets, allowing TILT to provide a differentiated B2B platform capable of supporting independent brands, U.S. MSOs and Canadian LPs. We expect 2021 to be an exciting year as we continue our transition from being a holding company possessing a disparate collection of subsidiaries to an integrated operating company capable of benefitting from economies of scale and cross-selling opportunities.” Financial Highlights from Continuing Operations for the Quarter Ended December 31, 2020 Revenue of $42.3 million, an 8.1% increase from the third quarter of 2020 and an increase of 35.4% from the prior year period.Gross margin before fair value adjustments of 26.7%, down 460 basis points (“bps”) from the third quarter of 2020 and up 200 bps from the prior year period. Operating expenses less non-cash adjustments for stock compensation, depreciation/ amortization and one-time charges was $8.3 million, flat compared to the third quarter and a 17.7% decline from the prior year period.Positive Adjusted EBITDA for the fourth consecutive quarter at $4.5 million.Cash and cash equivalents of $7.4 million, a $3.1 million increase from the previous quarter, due to robust cashflow from operations.Working Capital of $57.4 million, an $8.5 million increase from the previous quarter. Operational Highlights for the Quarter Ended December 31, 2020 Jupiter Research LLC’s (“Jupiter”) power supply revenue doubled from Q3 2020 to Q4 2020.Standard Farms, LLC (“Standard Farms”) posted record revenue for the quarter, including the two highest sales months in Company history.Standard Farms doubled extraction processing capacity during the quarter.Commonwealth Alternative Care, Inc.’s (“CAC”) lab and kitchen production capacity increased 100% during the quarter; cultivation expansion approved October 2020 planted during Q4 2020 and yielded first harvest in March 2021.Completed sale of Blackbird. Operational Highlights Subsequent to Quarter End Closed acquisition of Standard Farms Ohio LLC.Jupiter saw record cartridge shipments in January and record orders in February.Jupiter received ISO 13485:2016 Medical Device Certification.Launch of Her Highness NYC branded products in Massachusetts within 30 days of signing manufacturing and distribution contract.CAC completed planting in its eight additional grow rooms in Massachusetts during the quarter.Standard Farms had its highest flower sales during the month of March. Earnings Call and Webcast The Company will host a webcast at 8:00 AM EDT to discuss financial and operational results for the reported quarter. The live webcast may be accessed from the Events and Presentations menu in the Investor Relations section of the Company’s website at https://investors.tiltholdings.com/ir-calendar or to access the conference call via telephone, please dial, 1-877-705-6003. Please register at least 15 minutes prior to the scheduled start to download and install any necessary audio software. A replay of the webcast will be available in the Past Events section of the Company’s Investor Relations website approximately 2 hours after the live event and will be archived for 30 days. About TILT TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 35 states in the U.S., as well as Canada, Israel, Mexico, South America and the European Union. TILT’s core businesses include Jupiter, a wholly owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations, CAC in Massachusetts, Standard Farms in Pennsylvania and Standard Farms Ohio, LLC. TILT is headquartered in Phoenix, Arizona. For more information, visit www.tiltholdings.com. Forward-Looking Information This news release contains forward-looking information based on current expectations. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information may include, without limitation, expectations regarding 2021 revenue and Adjusted EBITDA guidance, the anticipated transition from a holding company to an integrated operating company capable of benefitting from economies of scale and cross-selling opportunities, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT. Generally, forward looking information can be identified by the use of forward looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including TILT’s experience and perceptions of historical trends, the ability of TILT to maximize shareholder value, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. TILT assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law. By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of TILT, and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements. For additional information regarding forward-looking statements and their related risks, please refer to the “Risk Factors and Uncertainties” section in the Management Discussion and Analysis of the Company for the quarter and year ended on December 31, 2020, which is available on the Company’s SEDAR profile at www.sedar.com. Non-IFRS Financial and Performance Measures In addition to providing financial measurements based on International Financial Reporting Standards (“IFRS”), the Company provides additional financial metrics that are not prepared in accordance with IFRS. Management uses non-IFRS financial measures, in addition to IFRS financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. These non-IFRS financial measures are EBITDA and Adjusted EBITDA. Management believes that these non-IFRS financial measures reflect the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-IFRS financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-IFRS financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results. As there are no standardized methods of calculating these non-IFRS measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. EBITDA and Adjusted EBITDA EBITDA and Adjusted EBITDA are financial measures that are not defined under IFRS. The Company uses these non-IFRS financial measures, and believes they enhance an investor’s understanding of the Company’s financial and operating performance from period to period, because they exclude certain material non-cash items and certain other adjustments management believes are not reflective of the Company’s ongoing operations and performance. The Company calculates EBITDA as net income (loss), plus (minus) income taxes (recovery), plus (minus) finance expense (income), plus depreciation and amortization expense. Adjusted EBITDA excludes certain one-time, non-cash or non-operating expenses, as determined by management, including stock compensation expense, business acquisition expense, debt issuance costs, severance, unrealized (gain) loss on changes in fair value of biological assets and fair value changes in biological assets included in inventory sold. Reconciliations of Non-IFRS Financial and Performance MeasuresAdjusted EBITDA is reconciled to Net Loss below as well as the section labelled “Reconciliation of Net Income (Loss) to Non-IFRS Measures” in the Management Discussion and Analysis of the Company for the quarter and year ended on December 31, 2020, which is available on the Company’s SEDAR profile at www.sedar.com. Selected Financial Results Table 1: Income Statement:(in US$ thousands, unaudited) Three Months Ended Year Ended($ thousands)Dec 31, 2020 Sep 30, 2020 Dec 31, 2019 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018Revenue$42,265 $39,083 $31,225 $158,409 $146,935 $ 3,502 Cost of Goods Sold 30,985 26,846 23,517 111,738 106,236 3,360Gross Profit, Before FV Adj. 11,280 12,237 7,708 46,671 40,699 142Gross Margin %, Before FV Adj. 26.7% 31.3% 24.7% 29.5% 27.7% 4.1%Gain on FV of Bio. Assets 13,650 14,477 9,250 47,298 37,459 151FV of Bio. Assets in Inventory Sold -14,063 -7,870 -5,348 -35,014 -19,790 -Gross Profit, After FV Adj. 10,867 18,844 11,610 58,955 58,368 293 Gross Margin %, After FV Adj. 25.7% 48.2% 37.2% 37.2% 39.7% 8.4%Total Operating Expenses 49,703 14,453 38,613 93,552 170,354 56,582Income (Loss) from Continuing Operations -38,836 4,391 -27,003 -34,597 -111,985 (56,289)Total Other Income (Expense) -15,841 -2,476 -9,200 -22,552 -13,217 (493,782)Income Tax Expense (Recovery) -9,313 3,639 -4,582 -5,043 -3,275 48Net (Loss) from Continuing Operations -45,364 -1,724 -31,621 -52,107 -121,927 (550,119)Net (Loss) from discontinued operations, net of tax -46,783 -2,893 -1,050 -53,650 -11,447 -Net (Loss)$(92,147) $(4,617) $(32,671) $(105,757) $(133,374) $(550,119) EBITDA, Non-IFRS -49,612 9,673 -27,881 -29,032 -89,022 (551,621)Adjusted EBITDA, Non-IFRS$ 4,545 $ 5,063 $ 1,564 $ 16,924 $ (845) $ (22,634) Table 2: Reconciliation of Non-IFRS Measures:(in US$ thousands, unaudited) Three Months Ended Year Ended($ thousands)Dec 31, 2020 Sep 30, 2020 Dec 31, 2019 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018Net (Loss) from Continuing Operations$(45,364) $(1,724) $(31,621) $(52,107) $(121,927) $(550,119) Add (Deduct) Impact of: Interest (Income) (1,595) (767) (843) (3,835) (3,280) (2,199)Finance Expense 1,847 2,981 4,398 10,336 13,463 -Income Tax Expense (Recovery) (9,313) 3,639 (4,582) (5,043) (3,275) 48Depreciation and Amortization 4,813 5,544 4,767 21,617 25,997 649Total Adjustments (4,248) 11,397 3,740 23,075 32,905 (1,502) EBITDA (Non-IFRS)$(49,612) $ 9,673 $(27,881) $(29,032) $(89,022) $(551,621) Add (Deduct) Impact of: Stock Compensation Expense 817 1,456 2,914 4,200 75,628 28,967Business Acquisition Expense - - 1,020 - 2,440 4,047Debt Issuance Costs - - 540 - 209 -Severance - - 1,026 279 1,204 -Foreign Exchange (Gain) Loss - - - - (76) 107(Gain) Loss on Sale of Assets (32) 102 598 70 610 -Lease Restructuring Costs - - - 280 - -Legal Settlement 275 - - 275 - -Unrealized (Gain) Loss on Investment in Equity Security 23 301 - 337 - -Loss on Loan Receivable 16,416 - 4,689 16,416 4,689 -One time bad debt expense 2,169 - - 2,169 - -Impairment (Recovery) of Inventory - - - - (1,418) 1,418Derecognition and impairment loss 34,076 138 22,560 34,214 22,560 494,448Unrealized (Gain) on Changes in FV of Bio. Assets (13,650) (14,477) (9,250) (47,298) (37,459) -FV Changes in Bio. Assets Included in Inventory Sold 14,063 7,870 5,348 35,014 19,790 -Total Adjustments 54,157 (4,610) 29,445 45,956 88,177 528,987 Adjusted EBITDA (Non-IFRS)$ 4,545 $ 5,063 $ 1,564 $16,924 $ (845) $(22,634) Table 3: Condensed Consolidated Statements of Cash Flow:(in US$ thousands, unaudited) Year Ended Dec 31, 2020 Year Ended Dec 31, 2019Cash provided by (used in) operating activities - continuing operations 16,693 (17,551)Cash (used in) operating activities - discontinuing operations (7,040) (10,404)Net cash provided by (used in) operating activities 9,653 (27,955) Cash (used in) investing activities - continuing operations (2,578) (95,962)Cash provided by (used in) investing activities - discontinuing operations 58 (275)Net cash (used in) investing activities (2,520) (96,237) Cash (used in) provided by financing activities - continuing operations (2,275) 29,145 Cash (used in) provided by financing activities - discontinuing operations (638) (633)Net cash (used in) provided by financing activities (2,913) 28,512 Effect of foreign exchange on cash and cash equivalents 627 1,012 Net change in cash and cash equivalents 4,847 (94,667) Cash and cash equivalents, beginning of year 2,579 97,247 Cash and cash equivalents, end of year$ 7,427 $ 2,579 Table 4: Condensed Consolidated Statements of Financial Position (Select Items) (in US$ thousands, unaudited): ($ thousands)Dec 31, 2020 Dec 31, 2019 Cash and Cash Equivalents$7,427 $2,580 Biological Assets 11,201 8,580 Inventory 52,634 48,169 Total Current Assets 101,889 94,708 Property, Plant & Equipment, Net 66,795 80,576 Total Assets 429,604 545,903 Total Current Liabilities 44,488 50,365 Total Long-Term Liabilities 102,069 111,672 Total Shareholders’ Equity 283,047 383,866 Working Capital 57,401 44,343 The CSE has neither approved nor disapproved the contents of this news release. Investor Relations Contact:Taylor Allisoninvestors@tiltholdings.com Media Contact:Ellen MellodyEllen@mattio.com570-209-2947

  • TILT Holdings Bolsters Human Resources and Marketing Leadership, Appoints Darryl K. Henderson, J.D. as Senior Vice President of Human Resources and Roseann Valencia-Fernandez as Vice President of Marketing
    GlobeNewswire

    TILT Holdings Bolsters Human Resources and Marketing Leadership, Appoints Darryl K. Henderson, J.D. as Senior Vice President of Human Resources and Roseann Valencia-Fernandez as Vice President of Marketing

    Mr. Henderson and Ms. Valencia-Fernandez Bring Decades of Global Leadership and Cannabis Industry Experience Strengthening TILT’s TeamPHOENIX, April 13, 2021 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (CSE: TILT) (OTCQX: TLLTF), a provider of business solutions to the global cannabis industry that includes inhalation technologies, cultivation, manufacturing, processing, brand development and retail, is pleased to announce the appointments of Darryl K. Henderson, J.D., as senior vice president of human resources and Roseann Valencia-Fernandez as vice president of marketing. Mr. Henderson will deliver HR solutions across the Company’s portfolio and geographic footprint, while Ms. Valencia-Fernandez will oversee the planning, development and execution of TILT’s marketing strategy. Mr. Henderson and Ms. Valencia-Fernandez will both report directly to TILT’s President, Gary Santo. “As we execute our strategic initiatives, repositioning leadership within the organization is critical to both the success of our team and growth of the Company. By continuing to attract top-tier talent to our already robust team, we are arming our Company with the kind of resources that will lead to success in both the short-term and for years to come,” said Mr. Santo. “I expect Darryl and Roseann to be instrumental in shaping our corporate culture internally and externally, while positioning TILT as a visionary company that is inclusive, supportive and innovative.” Darryl K. Henderson, J.D., Senior Vice President of Human Resources With extensive business leadership and human resource management acumen, Mr. Henderson brings more than 30 years of experience as an HR executive, chief employment compliance officer, chief diversity officer, executive/leadership coach, entrepreneur, business management consultant, and employment and commercial lawyer. Most recently, he served as president of Keith Consulting Group and has been involved in the cannabis industry since 2014. He previously held leadership roles at Monsanto Company, First Union National Bank, Lowe’s Home Improvement and a startup cannabis technology company, Logistics Trust. He has served businesses located in the U.S., Canada, Mexico, Italy, Ireland and the UK. Mr. Henderson earned a J.D. from the University of Georgia School of Law and a B.A. in Economics from Emory University. He is also a member of SHRM and the American Bar Association. “I believe that taking care of people and doing what’s right for the business are complementary imperatives,” said Mr. Henderson. “I’m honored to join TILT, and believe we are positioned to do great things, and our people will continue to fuel that success. We have talented teams of innovators, specialists, collaborators and people committed to the Company’s success.” Roseann Valencia-Fernandez, Vice President of MarketingRoseann Valencia-Fernandez spent the last two decades as an impactful global marketing executive in the cannabis and beauty CPG industries with a strong foundation in digital marketing and e-commerce, story-telling marketing and product development. Roseann joins TILT from Advanced Nutrients, a cannabis plant nutrition company, where she oversaw global marketing campaigns, growth strategies and budget development. She has also held senior marketing leadership positions at Hain Celestial as the head of marketing, digital, e-commerce and CBD innovation, and L’Oréal USA as the director of global marketing and product development. “The cannabis marketing function plays a pivotal role in molding the development of this rapidly growing sector,” said Ms. Valencia-Fernandez. “A synergy among our internal teams and brand partners will help bring the Company’s high-quality products to market in a way that maximizes our impact in the marketplace. I’m thrilled to join such an innovative and solution-based organization with a vision to propel the cannabis industry forward and establish new opportunities within the space.” To learn more about TILT, visit www.tiltholdings.com. About TILT TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 35 states in the U.S., as well as Canada, Israel, Mexico, South America and the European Union. TILT’s core businesses include Jupiter Research LLC, a wholly owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations, Commonwealth Alternative Care, Inc. in Massachusetts, Standard Farms LLC in Pennsylvania and Standard Farms Ohio, LLC in Ohio. TILT is headquartered in Phoenix, Arizona. For more information, visit www.tiltholdings.com. Investor Relations Contact:Taylor Allisoninvestors@tiltholdings.com Media Contact:Ellen MellodyEllen@mattio.com570-209-2947 Source: TILT Holdings Inc.